CLINICAL_TRIALS
trial_result
· 2019-09-06
Clinical Trial Update: Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer [Phase 2]
Summary
Phase 2 clinical trial evaluating pegylated irinotecan NKTR-102 in relapsed small cell lung cancer has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Roswell Park Cancer Institute | Conditions: Recurrent Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-09-06